Wordt geladen...
PARK2 loss promotes cancer progression via redox-mediated inactivation of PTEN
Cancer and Parkinson disease (PD) derive from distinct alterations in cellular processes, yet there are pathogenic mutations that are unequivocally linked to both diseases. Here we expand on our recent findings that loss of parkin RBR E3 ubiquitin protein ligase (PRKN, best known as PARK2)—which is...
Bewaard in:
| Gepubliceerd in: | Mol Cell Oncol |
|---|---|
| Hoofdauteurs: | , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Taylor & Francis
2017
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5706935/ https://ncbi.nlm.nih.gov/pubmed/29209642 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/23723556.2017.1329692 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|